Myriad Genetics
MYGN
221 hedge funds and large institutions have $480M invested in Myriad Genetics in 2025 Q2 according to their latest regulatory filings, with 43 funds opening new positions, 90 increasing their positions, 54 reducing their positions, and 49 closing their positions.
2,234% more call options, than puts
Call options by funds: $2.45M | Put options by funds: $105K
67% more repeat investments, than reductions
Existing positions increased: 90 | Existing positions reduced: 54
3% less funds holding
Funds holding: 228 → 221 (-7)
4.7% less ownership
Funds ownership: 102.85% → 98.15% (-4.7%)
12% less first-time investments, than exits
New positions opened: 43 | Existing positions closed: 49
42% less capital invested
Capital invested by funds: $833M → $480M (-$352M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$17.4M |
| 2 |
D.E. Shaw & Co
New York
|
+$11.7M |
| 3 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$7.95M |
| 4 |
KLP
Kent Lake PR
Anasco,
Puerto Rico
|
+$7.38M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$6.95M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$40.7M |
| 2 |
EARNEST Partners
Atlanta,
Georgia
|
-$35.3M |
| 3 |
DGI
Disciplined Growth Investors
Minneapolis,
Minnesota
|
-$23.5M |
| 4 |
SEI Investments
Oaks,
Pennsylvania
|
-$21.4M |
| 5 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$20.2M |
MYGN Hedge Fund Activity: Q2 2025 in Review
221 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in Myriad Genetics (MYGN) for Q2 2025, worth a combined $480M — down 42% from $833M a quarter earlier.
Sellers outnumbered buyers: 49 funds closed out of MYGN and 43 opened new positions — a net loss of 6 holders — while 54 trimmed existing stakes and 90 added.
The largest buyer was Morgan Stanley, adding an estimated $17.4M. The largest seller was Wellington Management Group, exiting entirely with an estimated $40.7M sold.
- 221 institutional investors held Myriad Genetics (MYGN) as of Q2 2025, down from 228 in Q1 2025.
- Funds reported $480M of Myriad Genetics stock for Q2 2025, down 42% quarter-over-quarter.
- 43 funds opened new Myriad Genetics positions in Q2 2025 and 49 closed out, a net change of -6 holders.
- The largest Myriad Genetics buyer in Q2 2025 was Morgan Stanley, an estimated $17.4M added.
- The largest Myriad Genetics seller in Q2 2025 was Wellington Management Group, an estimated $40.7M sold.
Based on aggregated 13F filings for Q2 2025.